43 results about "Fetal growth" patented technology

The invention relates to the technical field of biomedical signal processing, and particularly discloses a fetal growth and development detection method and system based on intellectualization, and the method comprises the steps: obtaining a mixed physiological signal and a fetal movement signal, obtaining a fetal movement interference coefficient and an interference peak period through cross-correlation analysis, constructing an artifact monitoring vector, and predicting a signal deterioration probability; artifact separation is carried out; distinguishing physiological and non-physiological types of the artifact signal, and extracting a signal degradation event; and if the degradation event exists, analyzing a conduction relationship between the event and equipment sampling parameters through a rule engine, generating a main conduction path, constructing an artifact strategy mapping model, and outputting a parameter correction rule. The system comprises a fetal movement analysis module, an artifact separation module, a degradation analysis module and an equipment correction module. According to the method, the multi-dimensional feature analysis and the intelligent model are combined, so that the fetal physiological signal purity and the anomaly detection accuracy can be improved.

A system configured to enclose a premature fetus within an extracorporeal environment to promote growth of the fetus and increase viability of the fetus, The system includes a chamber having an interior space configured to enclose the fetus, a first fluid circuit that delivers sterile fluid to the chamber, and a second fluid system that transfers oxygen to the fetus. The system chamber includes a stop mechanism including a clamp and an actuator, the clanip positioned in the interior space, the actuator coupled to the clamp such that movement of the actuator moves the clamp, and the actuator positioned at least partially outside the interior space. A method of using the system to treat hyperbilirubinemia is also provided.

Provided are methods and compositions for using tissue kallikrein-1 (KLK1) to treat or prevent pregnancy disorders such as fetal growth restriction (FGR) and preeclampsia.

The present disclosure provides for a method of treating fetal growth restriction in a fetus comprising obtaining a blood sample from a pregnant subject; isolating cell-free fetal DNA from the blood sample; testing the cell-free fetal DNA for a first DNA methylation level of 0.5800 or less in a group of genes, wherein the group of genes comprises the genes of any one of Tables 19-21, wherein the first DNA methylation level is calculated via an average of all differentially methylated islands of cytosine and guanine dinucleotides separated by only one phosphate in the 5' to 3' direction (5'-C-phosphate-G-3') (CpGIs) in differentially methylated regions (DMRs); and when the first DNA methylation level is 0.5800 or less, selecting a treatment from the following: monitoring the fetus during pregnancy of the pregnant subject, tracking movements of the fetus, admitting the pregnant subject to a hospital prior to going into labor, inducing early delivery of the fetus, performing an emergency Cesarean section on the pregnant subject, administering corticosteroids to the pregnant subject, or administering corticosteroids to the fetus upon birth. Other related methods are disclosed herein.

The utility model belongs to the technical field of medical equipment, and particularly relates to a fetal growth and development monitoring disc which comprises a monitoring disc body and a shell wrapping the monitoring disc body and used for protecting the monitoring disc body. The shell comprises a shell body and a shell cover detachably connected with the shell body, and the shell body and the shell cover are both made of transparent materials. The monitoring disc can be used for calculating the expected date of birth during pregnancy and estimating the growth and development condition of a fetus according to all stages of the pregnancy, the monitoring disc body can be installed in the shell, the monitoring disc body can be shielded and protected after the shell cover is covered, dust can be prevented, water splashing can be prevented, and the monitoring disc body can be prevented from being scratched; the content on the monitoring disc body in the shell can be directly seen through the shell cover, and after the shell cover is detached and opened, the rotating disc of the monitoring disc body can be rotated according to the gestational week, so that the growth and development condition of a fetus can be evaluated according to the growth and development standard reference value of the fetus in the gestational week stage.

Provided are methods and compositions for using tissue kallikrein-1 (KLK1) to treat or prevent pregnancy disorders such as fetal growth restriction (FGR) and preeclampsia.

The invention relates to the technical field of ultrasound department, in particular to a dynamic ultrasonic measuring device for fetal growth monitoring, which comprises an ultrasonic probe body, a holding handle is sleeved outside the ultrasonic probe body, and the holding handle is in clearance fit with the ultrasonic probe body; a driving mechanism for pushing the ultrasonic probe body to move is arranged in the holding handle; a plurality of adjusting rods are fixedly connected to the periphery of the holding handle, and rollers are hinged to the ends, away from the holding handle, of the adjusting rods; the device further comprises a processing center, a plurality of first pressure sensors are fixedly connected to the top of the holding handle, and the first pressure sensors are used for measuring the real-time pressure value when the holding handle is attached to the body surface of the pregnant woman and sending the real-time pressure value to the processing center; the processing center is used for sending a pressure applying instruction and a rotating instruction to the driving mechanism based on the real-time pressure value; the fixing difficulty of an ultrasonic monitoring probe is reduced through control of the driving mechanism, a doctor is assisted in keeping the position of the ultrasonic probe, and it is guaranteed that blood flow signals of the umbilical artery are clearly captured.

The application discloses an ultrasound examination and clinical management method for a fetus with umbilical cord torsion and related equipment. The application triggers a suspected umbilical cord torsion risk identification process based on the complaint information of a pregnant woman, and determines whether to enter key ultrasound screening through preliminary assessment. Through multi-section analysis of ultrasound image data, the morphological characteristics of the umbilical cord are extracted, and whether the fetus has growth restriction is evaluated in combination with the fetal growth parameters to form an ultrasound key screening result. Based on the preliminary assessment result and the ultrasound screening result, the risk level of the fetus is determined, and a corresponding clinical intervention strategy is formulated according to the risk level. Through stratified screening, information fusion and risk grading, the standardized management of the fetus with suspected umbilical cord torsion is realized, the early identification ability of the umbilical cord torsion is improved, the timeliness of clinical intervention is improved, and effective decision support is provided for the clinic.

This invention discloses a method and related equipment for predicting and intervening in the risk of stillbirth related to umbilical cord torsion. The method acquires multimodal clinical data, including the pregnant woman's complaints and prenatal ultrasound examination information, and standardizes the data to extract core predictive factors such as changes in fetal movement, signs of umbilical cord root torsion, and fetal growth restriction, as well as auxiliary predictive factors such as abnormal amniotic fluid volume and abnormal placental-umbilical cord insertion, constructing a feature vector that the model can process. Based on a pre-trained risk prediction model, the risk of stillbirth related to umbilical cord torsion is quantitatively assessed, a comprehensive risk score is output, and risk levels are classified. Based on the risk level, a pre-set clinical intervention strategy is automatically matched to form standardized treatment recommendations, which are then output to the clinical terminal. This method overcomes the limitations of traditional methods that rely on low sensitivity of single ultrasound diagnosis, achieving early risk identification and tiered management.

The invention discloses a fetal growth restriction diagnostic reagent and method based on METTL1 regulation and control of SLC7A11 m7G modification. The diagnostic reagent comprises a reagent for specifically detecting the expression level of an METTL1 gene and a reagent for detecting the m7G modification level of the SLC7A11 gene. The diagnosis method comprises the following steps: collecting a placenta tissue sample of a pregnant woman, respectively detecting the m7G modification level of an SLC7A11 gene and the expression level of an METTL1 gene by utilizing a MeRIP-seq technology and a real-time fluorescent quantitative PCR technology, and realizing the diagnosis on the fetal growth limitation by combining the detection results of the m7G modification level and the expression level. By researching the m7G modification regulation mechanism of METTL1 to SLC7A11, a novel diagnostic marker and a novel diagnostic method are provided for fetal growth limitation, and the marker has the advantages of high specificity, high sensitivity, accurate result and the like, and can be widely applied to early diagnosis of clinical fetal growth limitation.

The application discloses a preparation method of self-assembled nanomedicine for improving fetal growth restriction and application thereof. Aspirin raw medicine, polyethyleneimine and phenyl borate are dissolved in dimethyl sulfoxide, and after being mixed uniformly, the mixture is placed into an ultrasonic cleaner until the medicine powder is completely dissolved, then the mixed solution is placed in a dialysis bag, and the organic solvent is removed by rotating dialysis in deionized water, finally, the solution in the dialysis bag is freeze-dried, and the self-assembled nanomedicine is obtained. The medicine is injected through a vein to improve the pathological pregnancy environment of hypoxia, oxidative stress and inflammation related to fetal growth restriction in a gestation period, and promote long-term growth and development of the development-restricted fetus. The self-assembling method is simple and easy to operate, low in price, and the organic solvent is easy to remove, and the stability is good and the immunogenicity is free. More importantly, under a treatment dose much higher than the treatment dose, the self-assembled nanomedicine has no toxicity to the mother and fetus, and the safety development of the fetus in the gestation period is ensured.

The present invention relates to determining the carrier status of Annexin A5 M2 haplotype of parents (both male and female) prior to and / or after pregnancy to minimize the risk of pregnancy complications, including, but not limited to, recurrent pregnancy loss (RPL), infertility, miscarriage, in vitro fertilization (IVF) failure, IUI failure, implantation failure, foetal growth restriction (FGR), small for gestational age (SGA) newborn, intra-uterine foetal death (IUFD), gestational hypertension (GH), pre-eclampsia (PE) and / or venous thromboembolism (VTE). Once M2 carrier status is determined, methods of intervention, including administration of low molecular weight heparin (LMWH) and / or other anti-coagulants can be administered either prior to and / or after pregnancy. Methods of detecting the carrier status as well as method of diagnosing and or predicting prognosis based on the M2 carrier status of a patient and / or couple is also contemplated.

The present invention discloses the application of Nrf2 in the auxiliary diagnosis of fetal lung hypoplasia caused by intrauterine growth restriction, belonging to the field of biotechnology. This study found that the knockout of the Nrf2 gene in mice with intrauterine growth restriction led to a decrease in the live birth rate compared with wild-type mice, a decrease in the birth weight of fetal mice and the appearance of catch-up growth, an exacerbation of asymmetric development, and an obstruction in the development of pulmonary blood vessels; the oxidative stress index in lung tissue was aggravated; the pyroptosis index GSDMD in lung tissue increased. Overexpression of Nrf2 can effectively inhibit the expression of GSDMD and inhibit cell pyroptosis. The above results indicate that Nrf2 plays an important protective role in the lung hypoplasia of IUGR. Overexpression of Nrf2 can play a role in preventing and / or alleviating fetal lung hypoplasia caused by intrauterine growth restriction, and detecting the content of Nrf2 can predict the development of the fetal lung.

The invention provides application of a reagent for detecting KAT5 or H2A.Zac in preparation of a product for diagnosing placenta-derived diseases, and relates to the technical field of biomedicine. Experimental research of the inventor finds that chromosomes of trophoblasts in placentas of patients with repeated pregnancy loss are unstable, and expression of KAT5 and H2A.Zac is remarkably reduced. Experiments prove that KAT5-mediated H2A. Zac reduction is a main reason for reduction of trophoblast chromosome stability, so that the KAT5-H2A. Zac pathway provides a new action target for diagnosis and treatment of placenta-derived diseases, diagnosis and / or treatment of placenta-derived diseases can be realized, a new treatment strategy is provided for clinical improvement of poor pregnancy outcome, and the application of the KAT5-H2A. Zac pathway in diagnosis and treatment of placenta-derived diseases is developed. Therefore, the health level of female fertility can be improved, and gestation complications such as abortion and fetal growth limitation can be reduced.

The present application discloses the use of anaerobic-sensitive antibiotics in the preparation of drugs for the treatment of preeclampsia. Fusobacterium nucleatum is closely related to the clinical phenotype of preeclampsia, and has the effect of directly inducing the occurrence of preeclampsia, and clarifies the key pathogenic bacteria of preeclampsia. Taking Fusobacterium nucleatum as a target for preeclampsia, using anaerobic-sensitive antibiotics to target and eliminate this strain can improve the phenotypes of preeclampsia including hypertension, proteinuria, fetal growth restriction, and placental dysplasia.

Marker panels and methods of using the markers in circulating DNA (cirDNA) in maternal blood and / or maternal urine for early detection of fetal growth disorders (FGDs) are disclosed herein. Use of these marker panels will enable accurate prediction of FGDs using a low invasive approach that can be implemented as early as the first gestational trimester.

The invention discloses a tetrahedral framework nucleic acid placenta targeted nano delivery system as well as a preparation method and application thereof. The functionalized tetrahedral framework nucleic acid nanostructure is formed by assembling six single-stranded DNA (deoxyribonucleic acid), and nucleotide sequences of the single-stranded DNA are shown as SEQ ID NO.1-6. The six-arm DNA tetrahedron nano-structure constructed by the invention has controllable nano-size, programmable characteristic and good molecular recognition characteristic, can endow a nano-carrier with marker recognition capability by taking a nucleic acid aptamer as a molecular navigation unit, is accumulated in placenta tissue under the action of active targeting or specific enrichment, and can be used for preparing a biomarker. Therefore, the enrichment efficiency of the medicine at the placenta part is obviously improved; the method is helpful for realizing intervention treatment on the limited growth of the fetus, reducing non-targeted exposure to the maternal body and the fetus, and improving the overall safety of treatment.

The invention relates to the technical field of lipidomics and human health, in particular to screening and application of a pregnancy maternal lipid biomarker with fetal growth limitation, and the lipid biomarker is selected from one or any combination of DG 14: 0 / 18: 2, DG 16: 0 / 20: 4, TG 14: 0 / 16: 0 / 18: 1, TG 14: 0 / 16: 0 / 18: 2, TG 16: 0 / 16: 0 / 18: 0 and TG 16: 0 / 16: 0 / 18: 1. The lipid biomarker provided by the invention can accurately diagnose the pathogenesis of the fetal growth restriction, and provides a specific and noninvasive diagnosis means for the fetal growth restriction.

The invention relates to the technical field of traditional Chinese medicine, and discloses a traditional Chinese medicine decoction for treating polycystic ovarian syndrome and application, the traditional Chinese medicine decoction for treating polycystic ovarian syndrome is prepared by decocting a traditional Chinese medicine composition; the traditional Chinese medicine composition is prepared from radix rehmanniae preparata, cortex cinnamomi, semen brassicae, baked ginger, rhizoma curcumae longae, deer-horn glue, raw licorice roots, fried hawthorn fruits, herba leonuri, Chinese rose flowers, rhizoma chuanxiong and radix angelicae sinensis. The traditional Chinese medicine decoction for treating the polycystic ovarian syndrome has a remarkable curative effect on the symptoms of PCOS or PCOS infertility patients, and can improve the thickness and form of endometrium, regulate the phase hormone level and improve the follicle quality and the periodic ovulation rate at the same time, so that the effects of improving the clinical pregnancy rate and the total effective rate and reducing the biochemical pregnancy and fetal parturition rate are achieved; the traditional Chinese medicine decoction for treating the polycystic ovarian syndrome can improve BBT and acne of PCOS infertility patients, has no toxic or side effect, is safe and reliable, and has good clinical application value.

The invention relates to a nutritional composition for improving nausea and vomiting in a gestation period and guaranteeing growth and development of fetuses. The health-care food is prepared from the following components in percentage by mass: 10.68 percent to 24.05 percent of carbohydrate, 17.93 percent to 36.41 percent of protein substances, 20.9 percent to 52.94 percent of fat substances, 8.55 percent to 18.37 percent of dietary fiber substances, 1.11 percent to 1.35 percent of compound vitamins, 11.17 percent to 37.27 percent of compound minerals and 1.20 percent to 2.38 percent of blueberry powder. According to the nutritional composition, various nutrients are reasonably matched and the content of each nutrient is regulated and controlled, under the synergistic effect of the nutrients, the attack frequency of nausea and vomiting in the gestation period can be remarkably reduced, nutrients needed in the gestation period can be comprehensively supplemented, the nutrition gap of pregnant women caused by vomiting is complemented, and the nutritional value of the pregnant women is improved. The feed meets the requirements of pregnant women during pregnancy, guarantees normal growth and development of fetuses, and is especially suitable for pregnant women with nausea and vomiting symptoms and needing nutrition support, so as to improve the health level of mothers and infants.

The invention discloses an intelligent analysis system and method for ultrasonic examination data in the obstetrics department, and the method comprises the steps: firstly, solving the problems of data inconsistency and characteristic incompatibility caused by the variation of the body position and section of a fetus through standardization processing and attitude-anatomy alignment based on a spatial transformation network; further, a multi-scale feature descriptor containing rich anatomical structure information is generated from the aligned high-dimensional feature map to replace a sparse traditional biological measurement value; and finally, carrying out time sequence trajectory modeling on a sequence formed by the feature descriptors, and deeply mining a dynamic process and an individualized trend of fetal growth. Through the mode, accurate feature registration of ultrasonic images of different gestational weeks can be realized, a personalized dynamic growth model reflecting growth rate and mode change is constructed, and a quantitative growth abnormality risk score is finally output, so that the capability of accurately predicting fetal growth abnormality in an early stage is remarkably improved.

The invention provides a growth curve fitting method and device, equipment and a storage medium, and the method comprises the steps: receiving a plurality of measurement samples sent by at least one ultrasonic machine, the measurement samples comprising measurement results of biological indexes which are related to the gestational age in pregnant woman information and represent the growth state of a fetus; according to the measurement result of each biological index, adding the plurality of measurement samples into corresponding biological index sets, and grouping the measurement samples in each biological index set according to gestational age; for each biological index, determining probability distribution parameters corresponding to each group of measurement samples in the corresponding biological index set, and fitting the probability distribution parameters to obtain a fetal growth curve under the biological indexes; manual participation is not needed, the efficiency of establishing the fetal growth curve suitable for a certain region is improved, and the accuracy and prediction effect of doctor diagnosis are improved.

The present application relates to the technical field of machine learning, in particular to a prediction system for fetal growth restriction, comprising: a collection module, which collects magnetic resonance images and ultrasound data for a patient; a feature extraction module, which extracts an image feature group from the magnetic resonance images, and extracts an ultrasound feature group from the ultrasound data; a joint prediction module, which generates a prediction result according to the image feature group and the ultrasound feature group. The beneficial effect lies in: in view of the problem that the measurement effect of the related indicators for fetal growth restriction in the prior art is poor, by extracting specific image features from the magnetic resonance images as the image feature group, a better representation effect can be achieved for whether the placenta has placental dysfunction, avoiding the influence of subjective factors caused by relying on subjective judgment and evaluation of doctors in the prior art, and by processing the ultrasound data to form the ultrasound feature group, the image feature group and the ultrasound feature group are combined, achieving higher prediction accuracy.

Method of prediction of pregnancy complications, such as preeclampsia, fetal growth restriction, gestational hypertension, small for gestational age fetus, preterm birth, and also detection of chronic hypertension. Pregnant women are screened to determine the expression profile of one or more miRNAs in whole peripheral venous blood collected in the period of 10th-13th gestational week, whereas said one or more miRNAs are selected from the group miR-1-3p, miR-16-5p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-21-5p, miR-24-3p, miR-26a-5p, miR-92a-3p, miR-100-5p, miR-103a-3p, miR-126-3p, miR-130b-3p, miR-133a-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-155-5p, miR-181a-5p, miR-195-5p, miR-210-3p, miR-221-3p, miR-342-3p, miR-499a-5p, and miR-574-3p.

This invention belongs to the field of microbial technology, specifically relating to the application of *Lactobacillus helveticus* ZJUIDS12 in preventing and treating microplastic-induced injuries in pets. This invention discloses the application of *Lactobacillus helveticus* ZJUIDS12 in the preparation of drugs for preventing and treating microplastic-induced injuries in pets. The accession number for *Lactobacillus helveticus* ZJUIDS12 is CGMCC NO.23997. The prevention and treatment of microplastic-induced injuries in pets includes: preventing intestinal damage caused by microplastics and preventing fetal growth restriction caused by microplastics.

The invention discloses a rumen bypass micronutrient for promoting growth and development of fetuses, the rumen bypass micronutrient is rumen bypass coated folic acid with the coating ratio of 45%, and the rumen bypass protection rate and the small intestine absorption rate of the rumen bypass coated folic acid with the coating ratio of 45% are optimal. According to the method, the pregnant Hu sheep is fed from mating to 55 days of pregnancy, so that the effect of remarkably improving the growth and development of the fetus is achieved, and indexes such as the weight, the body size and the muscle fiber development level of the fetus are remarkably improved. According to the method, the feeding period is effectively shortened, so that the total feeding amount and the adding cost of rumen bypass coated folic acid are reduced, the feeding benefit is maximized, and accurate feeding is realized.

The invention provides a fetal growth limitation intelligent prediction system and method based on double networks, and relates to the technical field of perinatal medical monitoring, and the system comprises a data collection and preprocessing module which is used for processing collected prenatal fetal heart related data and outputting high-quality data; the fetal heart signal feature extraction module is used for outputting fetal heart feature vectors by adopting a parallel architecture of a convolutional neural network and a long-short-term memory network; the multi-modal feature fusion module is used for outputting a fusion feature vector based on the double-tower structure architecture; the hierarchical classification prediction module is used for modeling a hierarchical structure of FGR clinical diagnosis by adopting a graph neural network GNN, and outputting prediction probabilities of FGR diagnosis, subtype classification and perinatal outcome in combination with an MC loss function optimization model; and the clinical decision support module is used for generating decision result suggestions and visual reports. And the clinical requirements of early accurate identification, subtype classification and perinatal outcome prediction are met.

The invention belongs to the technical field of biology, and particularly relates to application of nuciferine in preparation of a medicine for relieving pyroptosis of trophoblasts in preeclampsia. Nuciferine inhibits activation of NLRP3 inflammasomes and reduces caspase-1 cleavage and GSDMD mediated pyroptosis, so that placenta inflammation and dysfunction are relieved, and preeclampsia symptoms are improved. The nuciferine remarkably improves the symptoms of fetal growth limitation and placenta weight reduction of preeclampsia mice, and reduces placenta oxidative stress and inflammation level. In a cell model, nuciferine effectively reverses the pyroptosis phenotype of trophoblast cells, and the protein expression of NLRP3, cleaved-caspase-1, GSDMD-NT and IL-1beta is remarkably reduced. The application potential of nuciferine as a promising natural medicine in preeclampsia treatment is clarified, and the understanding of the relationship between inflammation and pyroptosis in preeclampsia pathogenesis is deepened.

The invention relates to a fetal growth limitation intelligent prediction method based on a hidden Markov model, and belongs to the field of fetal growth limitation prediction. The method comprises the following steps: carrying out early, middle and late pregnancy physiological index data acquisition, cleaning and preprocessing; dividing the marked and classified early, middle and late pregnancy physiological index data set into a training set and a test set; taking the pregnancy period as a time sequence, and taking the physiological indexes under early, middle and late pregnancy as observation features to construct a feature sequence; constructing and training hidden Markov models for the normal fetal sample group and the FGR fetal sample group by using the training set to obtain a normal state HMM (HMM-Normal) and an FGR state HMM (HMM-FGR); and respectively calculating log-likelihood values generated with the HMM-Normal and the HMM-FGR by using the samples in the test set, and determining whether the samples have the FGR risk by comparing the likelihood values. According to the method, the hidden factors appearing in the FGR can be continuously analyzed subsequently through a deep learning method.

The present invention discloses the use of chemokine XCL1 in the preparation of a drug for preventing adverse pregnancy outcomes in advanced-age pregnant women. The present invention discloses the use of chemokine XCL1 in preventing adverse pregnancy outcomes in advanced-age pregnant women, especially chemokine XCL1 improves fetal growth restriction, which plays an important role in the pregnancy process. By applying XCL1 recombinant protein, the phenotype of fetal growth restriction in advanced-age pregnant mice can be alleviated, the possibility of adverse pregnancy outcomes is reduced, and a new effective measure is provided for the clinical treatment of adverse pregnancy outcomes in advanced-age pregnant women in the late stage.